Burning Rock to Present Data on Its Early Detection ELSA-seq at ESMO Asia Virtual Congress 2020 – GlobeNewswire


GUANGZHOU, China, Oct. 20, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that new data for its early detection ELSA-seq test will be presented at the upcoming European Society for Medical Oncology (ESMO) Asia Virtual Congress, on Friday, November 20.

Early cancer detection can potentially offer clinical benefits, particularly for those without effective screening methods. As a pilot project, the THUNDER (the unintrusive detection of early-stage cancers) study has been designed for the development and validation of ELSA-seq, a blood-based targeted methylation sequencing test. By interrogating the epigenetic alterations from circulating cell-free DNA (cfDNA), ELSA-seq enabled sensitive detection and accurate localization of early-stage tumors (THUNDER-I), previously reported by a poster titled “Multiplatform analysis of early-stage cancer signatures in blood” at the American Association for Cancer Research (AACR) Special Conference on Advances in Liquid Biopsies in January 2020. Poster link here.

The mini oral presentation “Early detection and localization of multiple cancers using a blood-based methylation assay (ELSA-seq)” (abstract number 602/LBA3) will report results of the training and validation sets from the second THUNDER substudy (THUNDER-II), on malignancies developed in lung, liver, colon/rectum, esophagus, pancreas, and ovary.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

READ  Transit of Mercury today: How to watch incredibly rare celestial sight as planet crosses in front of the Sun

For more information about Burning Rock, please visit: www.brbiotech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.



READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here